Clinical Trials Browser

Phase NA × Completed × Trastuzumab × Clear all

NCT07115095 2025-08-11

Tumor Markers for Efficacy of Dual-Target Therapy in HER2+ Breast Cancer

Phase NA Completed

HER2-positive Breast Cancer

NCT01295086 2020-11-02

Taxotere®, Eloxatin® and Xeloda® (TEX) in Combination With Herceptin® as Treatment for HER2 Positive Non-resectable Cancer

Phase NA Completed

Adenocarcinoma

NCT00496808 2020-09-23

Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast

Phase NA Completed

69 enrolled 6 charts

Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT00681993 2019-01-22

PBIC

Phase NA Completed

Breast Neoplasms

NCT00847366 2018-03-15

Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple Myeloma

Phase NA Completed

BreastSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Sarcoma

NCT01048099 2016-01-29

Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer

Phase NA Completed

283 enrolled 8 charts

Breast Neoplasms, Neoplasm Metastasis

NCT00896376 2015-02-10

Trastuzumab in Treating Women With Metastatic Breast Cancer

Phase NA Completed

Breast Neoplasms

NCT00433407 2012-10-04

T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors

Phase NA Completed

BreastGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Breast Neoplasms, Male, Small Cell Lung Carcinoma